This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.
Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW . An UK myeloma forum phase II study of thalidomide: long term follow-up and recommendations for treatment. Leukemia Res 2003; 27: 909–914.
Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78: 34–39.
Blade J, Perales M, Rosinol L, Tuset M, Montoto S, Esteve J et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001; 113: 422–424.
Rosinol L, Cibeira MT, Blade J, Esteve J, Aymerich M, Rozman M et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832–836.
Biagi JJ, Mileshkin L, Grigg AP, Westerman DW, Prince HM . Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001; 28: 1145–1150.
Ribas C, Colleoni G, Almeida M, Duch CR, Ohashi C, Segreto R et al. Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma. Acta Oncol 2004; 43: 215–216.
Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, K., Helgason, H., van der Holt, B. et al. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas. Leukemia 19, 143–145 (2005). https://doi.org/10.1038/sj.leu.2403568
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403568
This article is cited by
-
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
Leukemia (2009)
-
Progress in drug therapy for multiple myeloma
Chinese Journal of Clinical Oncology (2008)